Previous Close | 4.49 |
1-Year Change | 9.78% |
6-Months Change | -41.31% |
3-Months Change | 12.25% |
Moving Avg (50d) | 4.1206 |
Moving Avg (200d) | 5.2548 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 3.13B |
Beta (3-Years) | 2.42 |
Revenue Growth (ttm) | 1218.71% |
Net Profit Margin (ttm) | -8016.83% |
Return On Assets (ttm) | -161.23% |
EPS (ttm) | -0.92 |
PE Ratio (ttm) | -4.88 |
Dividend Yield | % |
Asset Description: | ImmunityBio, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-19 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
4.998 | 4.845 | 4.743 | 4.59 | 4.335 | 4.08 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |